GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Inventories, Raw Materials & Components

APLM (Apollomics) Inventories, Raw Materials & Components : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Inventories, Raw Materials & Components?

Apollomics's inventories, raw materials & components for the quarter that ended in Jun. 2024 was $0.00 Mil.


Apollomics Inventories, Raw Materials & Components Historical Data

The historical data trend for Apollomics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Inventories, Raw Materials & Components Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
- - - -

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventories, Raw Materials & Components Get a 7-Day Free Trial - - - - -

Apollomics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Apollomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.